![Håkan Rosén](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Håkan Rosén
Director/Miembro de la Junta en Glucox Biotech AB .
Fortuna: 704 307 $ al 31/05/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Per Ingvar Oskar Wikström | M | 70 |
Glucox Biotech AB
![]() Glucox Biotech AB Pharmaceuticals: MajorHealth Technology Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden. | 21 años |
Johan Viberg | M | - |
Glucox Biotech AB
![]() Glucox Biotech AB Pharmaceuticals: MajorHealth Technology Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden. | - |
Björn Karl-Axel Sundeby | M | - |
Glucox Biotech AB
![]() Glucox Biotech AB Pharmaceuticals: MajorHealth Technology Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden. | - |
Alan Harris | M | - |
Glucox Biotech AB
![]() Glucox Biotech AB Pharmaceuticals: MajorHealth Technology Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Suecia | 4 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Håkan Rosén
- Red Personal